

성명: 임영석

생년월일: 1967년 12월 8일

전공: 소화기내과 (간)

e-mail: limys@amc.seoul.kr

학력: 1992년 서울의대 졸업

1997년 서울의대 내과학 석사

2002년 서울의대 내과학 박사

수련기관 및 기간:

1993년-1997년 서울대학교병원 내과 전공의

2000년-2002년 서울대학교병원 소화기내과 전임의

연수경력:

2007년 8월 1일 - 2008년 10월 30일 Mayo Clinic, Rochester, MN, USA

경력: 1997년 2월 - 2000년 4월 대한민국 공군 대위(군의원)

2002년 4월 - 2002년 2월 서울대학교병원 내과 촉탁조교수

2003년 3월 - 2008년 2월 울산의대 서울아산병원 소화기내과 조교수

2008년 3월 - 2014년 9월 울산의대 서울아산병원 소화기내과 부교수

2014년 10월 - 현재 울산의대 서울아산병원 소화기내과 교수

2015년 4월 - 2019년 6월 서울아산병원 임상시험센터 소장

2018년 3월 - 현재 울산의대 연구부학장

학회 활동:

2009년 - 2014년 10월 World Congress of Internal Medicine 조직위 등록위원장

2013년 - 2015년 대한간학회 기획이사 및 한국간재단 기획국장

2011년 - 2017년 대한간암학회 간암등록사업이사

2017년 - 2018년 대한간암학회 학술이사

2019/12 - 2021/11 대한간학회 총무이사 및 한국간재단 사무총장

2021/06 - 2022/03 아시아-태평양 간학회(APASL) 2022 통합개최위원회 위원장

수상: Emerging Leader, Asia-Pacific Digestive Week (APDW) 2015

Scientific Achievement Award of Asan Medical Center: 2010-2011, 2013-2019

보건복지부 장관 표창: 2017년

울산대학교 의과대학 올해의 교수상: 2017년

울산대학교 올해의 교수상: 2018년

서울대학교병원 내과 동문회 '합춘내과학술상': 2018년


관심 연구분야 :

Clinical Research in Hepatology - 만성 B형 및 C형 간염, 간암

h-index: 60 (Accessed in Google Scholar on 2020-07-13)

논문 인용 횟수: 2015년 이후 9077회 (Accessed in Google Scholar on 2020-07-13)

인용	모두 보기	
	전체	2015년 이후
서지정보	13484	9077
h-index	60	48
i10-index	231	173



대표 논문 5개 (As a Corresponding Author in the Original Articles Only)

1. Choi J, Kim HJ, Lee J, Cho S, Ko MJ, **Lim YS**. Risk of Hepatocellular Carcinoma Among Patients with Chronic Hepatitis B Treated with Entecavir vs Tenofovir: A Nationwide Cohort Study. **JAMA Oncology**. 2019 Jan 1;5(1):30-36. PMID: 30267080.
2. Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, Lee HC, **Lim YS**. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. **JAMA Oncology** 2018 May 1;4(5):661-669. PMID: 29543938
3. Kim SY, An J, **Lim YS**, Han S, Lee JY, Byun JH, Won HJ, Lee SJ, Lee HC, Lee YS. MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma. **JAMA Oncology**. 2017 Apr 1;3(4):456-463. PMID: 27657493
4. Kim HD, **Lim YS**, Han S, An J, Kim GA, Kim SY, Lee SJ, Won HJ, Byun JH. Evaluation of Early-Stage Hepatocellular Carcinoma by Magnetic Resonance Imaging with Gadoteric Acid Detects Additional Lesions and Increases Overall Survival. **Gastroenterology** 2015; 148:1371-1382. PMID: 25733098
5. **Lim YS**, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. **Gastroenterology**. 2014 June; 147(1): 152-161. PMID: 24583062

그 외 주요 논문 (As a Corresponding Author in the Original Articles Only)

6. Choi J, Jo C, **Lim YS**. Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection. **Hepatology**. [Epub ahead of print] PMID: 32324905
7. Choi WM, Choi J, **Lim YS**. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in

<p>Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. [Epub ahead of print] PMID: 32407970</p>
<p>8. Kim GA, Han S, Choi GH, Choi J, Lim YS. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther. 2020 Jun;51(11):1169-1179. PMID: 32291781</p>
<p>9. Choi J, Kim GA, Han S, Lim YS. Earlier ALT Normalization during Antiviral Treatment is Independently Associated with Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. Am J Gastroenterol. 2020 Mar;115(3):406-414. PMID: 31895708.</p>
<p>10. Liu K, Choi J, Le A, Yip TCF, Wong VWS, Chan SL, Chan HLY, Nguyen MH, Lim YS, Wong G. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. Aliment Pharmacol Ther 2019;50:1037–1048. PMID: 31524304.</p>
<p>11. Lim YS, Gwak GY, Choi J, Lee YS, Byun KS, Kim YJ, Yoo BC, Kwon SY, Lee HC. Monotherapy with Tenofovir Disoproxil Fumarate for Adefovir-Resistant vs. Entecavir-Resistant Chronic Hepatitis B: 5-Year Trials. J Hepatol 2019;71:35-44. PMID: 30876946</p>
<p>12. Choi GH, Kim GA, Choi J, Han S, Lim YS. High Risk of Clinical Events in Untreated HBeAg-Negative Chronic Hepatitis B Patients with High Viral Load and No Significant ALT Elevation. Aliment Pharmacol Ther. 2019 Jul;50(2):215-226. PMID: 31135074</p>
<p>13. Kim HL, An J, Park JA, Park SH, Lim YS, Lee EK. Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High Risk Patients with Cirrhosis. Hepatology 2019 Apr;69(4):1599-1613. PMID: 30365164</p>
<p>14. Choi J, Kim GA, Han S, Lee W, Chun S, Lim YS. Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early Stage Hepatocellular Carcinoma. Hepatology. 2019 May;69(5):1983-1994. PMID: 30153338.</p>
<p>15. Kim GA, Lim YS, Han S, Choi, J, Shim JH, Kim KM, Lee HC, Lee YS. High Risk of Hepatocellular Carcinoma and Death in Patients with Immune-Tolerant Phase Chronic Hepatitis B. Gut 2018 May;67(5):945-952. PMID: 29055908</p>
<p>16. Choi J, Han S, Kim N, Lim YS. Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population. Hepatology. 2017 Nov;66(5):1454-1463. PMID: 28628942</p>
<p>17. Kim GA, Han S, Kim HD, An J, Lim YS. Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis B vs Chronic Hepatitis C after Achievement of Virologic Response. J Viral Hepat. 2017 Nov;24(11):990-997. PMID: 28499070</p>
<p>18. Lim YS, Lee YS, Gwak GY, Byun KS, Kim YJ, Choi J, An J, Lee HC, Yoo BC, Kwon SY. Monotherapy with Tenofovir Disoproxil Fumarate for Multiple Drug-Resistant Chronic Hepatitis B: 3-Year Trial. Hepatology. 2017 Sep;66(3):772-783. PMID: 28370419</p>
<p>19. Lim YS, Yoo BC, Byun KS, Kwon SY, Kim YJ, An J, Lee HC, Lee YS. Tenofovir Monotherapy vs Tenofovir and Entecavir Combination Therapy in Adefovir-Resistant Chronic Hepatitis B Patients With Multiple Drug Failure: Results of a Randomized Trial. Gut 2016;65:1042–1051.</p>
<p>20. Lim YS, Byun KS, Yoo BC, Kwon SY, Kim YJ, An J, Lee HC, Lee YS. Tenofovir Monotherapy vs</p>

Tenofovir and Entecavir Combination Therapy in Entecavir-Resistant Chronic Hepatitis B Patients With Multiple Drug Failure: Results of a Randomized Trial. **Gut** 2016;65:852–860.

21. Kim GA, **Lim YS**, An J, Lee D, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis b: clinical outcomes and durability. **Gut**. 2014 July; 63(8): 1325-1332.
22. An J, Kim KW, Han S, Lee J, **Lim YS**. Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy. **Aliment Pharmacol Ther** 2014;39:1418-1426.
23. Kim GA, **Lim YS**, An J, Lee D, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. **Gut** 2014;63:1325-1332.
24. Heo NY, **Lim YS**, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. **J Hepatol** 2010;53:449-454.
25. Park SJ, **Lim YS**, Hwang S, Heo NY, Lee HC, Suh DJ, Yu E, Lee SG. Emergency adult-to-adult living-donor liver transplantation for acute liver failure in a hepatitis B virus endemic area. **Hepatology** 2010;51:903-911.
26. **Lim YS**, Larson TS, Benson JT, Kamath PS, Kremers WK, Therneau TM, Kim WR. Serum sodium, renal function, and survival of patients with end-stage liver disease. **J Hepatol** 2010;52:523-528.
27. **Lim YS**, Oh HB, Choi SE, Kwon OJ, Heo YS, Lee HC, Suh DJ. Susceptibility to type 1 autoimmune hepatitis is associated with shared amino acid sequences at positions 70-74 of the HLA-DRB1 molecule. **J Hepatol** 2008;48:133-139.
28. Kim IS, **Lim YS**, Lee HC, Suh DJ, Lee YJ, Lee SG. Pre-operative transarterial chemoembolization for resectable hepatocellular carcinoma adversely affects post-operative patient outcome. **Aliment Pharmacol Ther** 2008;27:338-345.